Dr. John Cush RheumNow
9 months ago
APP Pearls “When seeing a new patient, never assume that their preconceived or prior diagnosis is the only rheumatology condition that they have” - Lindsay Tom, PA-C
Dr. John Cush RheumNow
9 months ago
Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology?
Recent large-scale clinical trials have broadened therapeutic options for SARD-ILD beyond immunosuppressants, offering new hope for patients with these serious conditions.
https://t.co/RLlOdEWTOa https://t.co/UI9cdJ5Ovd
Pregnancy in SLE gets a lot of press in the rheumatology literature, and deservedly so, since pregnancy risks can be markedly increased. It was not that many years ago that women with SLE were counseled to avoid pregnancy.
Dr. John Cush RheumNow
9 months ago
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest results from a Phase 3 trial presented at ACR 2025, sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/Tm8m43ZXBM https://t.co/GWLPR5y3d2
Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, if not overly aggressive, in treating all RA patients. And my view was that HCQ was representative of under-treatment. I have reconsidered the use of HCQ in RA substantially in the last few years, based
Dr. John Cush RheumNow
9 months ago
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
https://t.co/2NFwTllLZa https://t.co/S7Cwzbgnde
Dr. John Cush RheumNow
9 months ago
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025
https://t.co/yzQVt1fLKW https://t.co/hrbEeppZhW
Dr. John Cush RheumNow
9 months ago
APP Pearls “Point out to every patient with gout that poorly controlled gout will increase their risk of CV events and mortality” - Emma Bavage, NP
Dr. John Cush RheumNow
9 months ago
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
Dr. John Cush RheumNow
9 months ago
Best of 2025: Methotrexate intolerance in rheumatoid arthritis
Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however, there is significant intolerance to this drug among adult RA patients - especially at doses above 15 mg per week. https://t.co/hzfF7UVKVI
Dr. John Cush RheumNow
9 months ago
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis
The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. https://t.co/KacbtcMn5G
Dr. John Cush RheumNow
9 months ago
Algorithm for the treatment of calcinosis #calcinosis #ACR24 https://t.co/NZhP7Enzrp https://t.co/I0HLtYjzgb
Dr. John Cush RheumNow
9 months ago
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/PTJPhcvnzC
Dr. John Cush RheumNow
9 months ago
Best of 2025: Overview of the VEXAS Syndrome
A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.
https://t.co/O3BoOElcbT https://t.co/0hSEWqMFVf
Dr. John Cush RheumNow
9 months ago
Inflammatory vs. Noninflammatory Pain
https://t.co/ZZLMnT8IVO https://t.co/dnZHqV1jcK

